

Independent Auditor's Review Report on consolidated unaudited financial results of Independent Auditor's for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.
4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly Owned Subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly Owned Subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly Owned Subsidiary of AEU
5	Cal India Foods International ('CAL')	Wholly Owned Subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly Owned Subsidiary of CAL



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

7	JC Biotech Private Limited	Subsidiary
8	Scitech Specialities Private Limited	Subsidiary
9	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly Owned Subsidiary
10	Evovx Technologies GmbH	Wholly Owned Subsidiary of AEEBV
11	Saiganesh Enzytech Solutions Private Limited	Subsidiary
12	Starya Labs Inc.	Wholly Owned Subsidiary of AEU
13	Advanced Nutrazyme Private Limited	Wholly Owned Subsidiary (with effect from July 04, 2025)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of four subsidiaries included in the Statement, whose interim financial information (before consolidation adjustment) reflects total revenues of Rs. 601.80 million, total net profit after tax of Rs. 24.90 million and total comprehensive income of Rs. 24.92 million, for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by the other auditors whose reports have been furnished to us by the Management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. One Subsidiary is located outside India whose interim financial information has been prepared in accordance with the accounting principles generally accepted in their respective country and which has been reviewed by other auditor under generally accepted auditing standards applicable in their respective country. The Holding Company's Management has converted the interim financial information of such subsidiary located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India.

We have reviewed these conversion adjustments made by the Holding Company's Management. Our conclusion on the Statement, in so far as it relates to the interim financial information of such subsidiary located outside India is based on the report of other auditor and the conversion adjustments prepared by the Management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of the above matter.



Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India

Tel: +91 22 6974 0200 | LLPIN: ACT-3789

Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune www.mska.in

MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

8. The Statement includes the interim financial information of four subsidiaries which has not been reviewed by their auditors, whose interim financial information (before consolidation adjustment) reflects total revenue of Rs. 77.16 million, total net profit after tax of Rs. 14.09 million and total comprehensive income of Rs. 14.09 million, for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such Management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on these interim financial information certified by the Management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187


Amrith Vaidya

Partner

Membership No.: 101739

UDIN: 26101739KIPUEZ6689



Place: Mumbai

Date: August 08, 2026

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No:91-22-41703220, Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id: sanjay@advancedenzymes.com

Statement of unaudited consolidated financial results for the quarter ended 30 June 2026

(₹ in million except per share data)

Particulars	Quarter ended			
	30-Jun-26 Unaudited	31-Mar-26 Audited (refer note vi)	30-Jun-25 Unaudited	31-Mar-26 Audited
1 Revenue from operations	1,897.88	2,033.67	1,859.14	7,457.57
2 Other Income	130.21	72.28	88.50	348.32
3 Total Income (1+2)	2,028.09	2,105.95	1,947.64	7,805.89
4 Expenses				
(a) Cost of materials consumed	545.02	559.61	439.70	1,943.12
(b) Purchases of stock-in-trade #	0.01	0.00	-	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(48.14)	9.69	60.79	(13.61)
(d) Employee benefits expense (refer note iv)	445.52	419.38	397.13	1,622.86
(e) Finance costs (including exchange difference)	5.80	5.73	7.64	26.28
(f) Depreciation and amortisation expense	98.79	101.92	96.18	400.93
(g) Other expenses	445.83	412.71	397.20	1,614.54
Total Expenses	1,492.83	1,509.04	1,398.64	5,594.12
5 Profit before exceptional item and tax (3-4)	535.26	596.91	549.00	2,211.77
6 Exceptional item (charge / (credit)) (refer note ix & x)	-	(1.13)	-	(113.59)
7 Profit before tax (5-6)	535.26	598.04	549.00	2,325.36
8 Tax expense				
Current tax	150.65	133.48	154.70	564.46
Deferred tax charge / (credit)	(1.28)	12.04	(10.10)	24.82
Total tax expense	149.37	145.52	144.60	589.28
9 Net profit for the period (7-8)	385.89	452.52	404.40	1,736.08
10 Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss				
Remeasurements of defined benefit liability/(asset)	0.02	6.05	(0.57)	13.40
(ii) Income tax related to items that will not be reclassified to profit or loss	(0.01)	(1.50)	0.16	(3.37)
B (i) Items that will be reclassified to profit or loss				
Exchange differences in translating financial statements of foreign operations	(14.28)	474.78	38.12	938.08
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-
Total Other comprehensive income	(14.27)	479.33	37.71	948.11
11 Total comprehensive income (9+10)	371.62	931.85	442.11	2,684.19
12 Net profit attributable to:				
Shareholders of the Company	370.93	429.63	399.30	1,687.19
Non-controlling interest	14.96	22.89	5.10	48.89
13 Other comprehensive income attributable to:				
Shareholders of the Company	(14.27)	479.16	37.73	947.42
Non-controlling interest #	0.00	0.17	(0.02)	0.69
14 Total comprehensive income attributable to:				
Shareholders of the Company	356.66	908.79	437.03	2,634.61
Non-controlling interest	14.96	23.06	5.08	49.58
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.95	223.85	223.76	223.85
16 Other equity				16,095.72
17 Earnings Per Share of ₹ 2 each (not annualized)				
(a) ₹ (Basic)	3.31	3.84	3.57	15.08
(b) ₹ (Diluted)	3.31	3.84	3.57	15.06

Figures are below Rs. 0.01 Million, hence disclosed as Rs. 0.00



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Nutrazyme Private Limited (India)(w.e.f. 4 July 2025), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Starya Labs, Inc. (U.S.A.), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 8 August 2026. The above results have been reviewed by the statutory auditors of the Company and they have expressed an unmodified conclusion. The review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iv) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(v) The Group has allotted 49,350 equity shares during the quarter ended 30 June 2026 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(vi) The figures for the quarter ended 31 March 2026 as reported in these unaudited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(vii) The Board of Directors in its meeting held on 9 May 2026 had proposed the final dividend for the financial year 2025-26 of Rs. 1.35/- per equity share and the same has been approved by the shareholders of the Company in its Annual General Meeting held on 31 July 2026 and paid on 5 August 2026.

(viii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(ix) On November 21, 2025, the Government of India had notified the four Labour Codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 – consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations.

The Group had assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. The assessment was based on the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented such incremental impact under "Exceptional Items" in the consolidated financial results.

The impact for the quarter ended 31 December 2025 consisting of gratuity of Rs. 45.67 million and compensated absences of Rs. 1.51 million was accounted in the consolidated financial results primarily due to change in wage definition. Further, for the quarter ended 31 March 2026, additional impact of gratuity of Rs. 0.63 million had been recognised. The impact for the year ended 31 March 2026 pertaining to gratuity was Rs. 46.30 million and compensated absences is Rs. 1.51 million.

(x) On 22 August 2025, United States court of appeals had directed the District of Arizona to pass the order in favour of Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzyme USA, Inc. (U.S.A.) for the lawsuit filed by the Competitor. Based on the above direction of United States Court of Appeals and legal opinion received in the quarter ended 31 December 2025, the provision created amounting to Rs. 159.64 million earlier with respect to the mentioned lawsuit was reversed. Further, for the quarter ended 31 March 2026, additional impact of Rs. 1.75 million had been recognised on account of foreign exchange fluctuation. The cumulative impact for the year ended 31 March 2026 pertaining to the above mentioned lawsuit is Rs. 161.39 million

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018



M.M. Kabra
Wholtime Director
DIN : 00148294

Place: Thane
Dated: 8 August 2026

